Indication
Ph+ ALL
3 clinical trials
6 products
1 drug
Clinical trial
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic LeukemiaStatus: , Estimated PCD: 2023-09-01
Product
PonatinibClinical trial
A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)Status: Recruiting, Estimated PCD: 2025-11-01
Product
ABL001Product
DasatinibProduct
PrednisoneProduct
BlinatumomabClinical trial
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)Status: Recruiting, Estimated PCD: 2024-12-31
Drug
OlverembatinibProduct
Imatinib